SC
AMLX icon

Steven Cohen’s Amylyx Pharmaceuticals AMLX Stock Holding History

Steven Cohen’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-106,535
Closed -$1.65M – 3963
2026
Q1 		$1.48M Sell
106,535
-228,465
-68% -$3.21M ﹤0.01% 2511
2025
Q4 		$4.05M Sell
335,000
-2,455,066
-88% -$33.3M ﹤0.01% 1986
2025
Q3 		$37.9M Sell
2,790,066
-1,746,200
-38% -$16.4M 0.06% 328
2025
Q2 		$29.1M Buy
4,536,266
+3,619,300
+395% +$17.6M 0.06% 378
2025
Q1 		$3.25M Buy
+916,966
New +$3.26M 0.01% 1094
2024
Q4 		– Sell
-200
Closed -$648 – 2058
2024
Q3 		$648 Buy
+200
New +$450 ﹤0.01% 1931
2024
Q2 		– Sell
-170,000
Closed -$483K – 1829
2024
Q1 		$483K Sell
170,000
-2,581,305
-94% -$33.8M ﹤0.01% 1659
2023
Q4 		$40.5M Buy
2,751,305
+2,751,259
+5,980,998% +$42.2M 0.1% 260
2023
Q3 		$842 Sell
46
-7,061
-99% -$149K ﹤0.01% 2370
2023
Q2 		$153K Sell
7,107
-317,693
-98% -$8.58M ﹤0.01% 1482
2023
Q1 		$9.53M Sell
324,800
-1,803,160
-85% -$62.6M 0.03% 561
2022
Q4 		$78.6M Buy
2,127,960
+1,660,999
+356% +$58.9M 0.27% 90
2022
Q3 		$13.1M Buy
466,961
+154,500
+49% +$3.85M 0.05% 433
2022
Q2 		$6.02M Buy
+312,461
New +$3.71M 0.03% 654

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Steven Cohen's AMLX Position: Q2 2026 in Review

Steven Cohen sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 106,535 shares — an estimated $1.65M sold.

Steven Cohen first reported a position in AMLX in Q2 2022 and held it in 14 quarters. The position peaked at $78.6M in Q4 2022. 205 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Steven Cohen reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 106,535 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
  • Steven Cohen first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 14 quarters.
  • Steven Cohen's Amylyx Pharmaceuticals position peaked at $78.6M in Q4 2022.
  • 205 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.